Terminal2 — Card #06: Prostate Cancer

S01 Everyone

What Is It

Definition, mechanism, and the clinical reality of metastatic prostate cancer at end of life. What the hospice team needs to understand on day one.

US New Cases/Year

~299,000

Most commonly diagnosed cancer in men; second leading cause of male cancer death in the US.^[22]

Bone Met Prevalence

~90%

~90% of mCRPC develops bone metastases — the dominant hospice management challenge.^[22]

mCRPC Median OS

13–33 mo

Wide range reflects sequential therapy options and long natural history unique to prostate cancer.

Osteoblastic Lesion Type

Osteoblastic

Predominantly osteoblastic — mechanically weak despite appearing dense on imaging. Fracture risk is real, pain is undertreated because scans look "stable."

Prostate cancer has a distinctly long natural history — patients often live years or even a decade with metastatic hormone-sensitive disease before progressing to castration-resistant prostate cancer (CRPC). Approximately 90% of men with metastatic prostate cancer develop bone metastases.^[22] Unlike breast cancer's osteolytic bone destruction, prostate cancer produces predominantly osteoblastic lesions — abnormal bone formation that is denser but mechanically weak, predisposing to fracture, pain, and spinal cord compression. This paradox — dense-appearing but fragile bone — leads to systematic undertreament of pain because imaging looks "stable."

The disease progresses through well-defined stages: hormone-sensitive (mHSPC, responds to ADT, median 18–36 months), non-metastatic CRPC (rising PSA, no visible mets), and metastatic CRPC (mCRPC, median OS 13–33 months depending on treatment line). By the time a patient reaches hospice, he has typically been on ADT for years, enduring hot flashes, sexual dysfunction, muscle loss, and osteoporosis — a compounding legacy of treatment toxicity layered on top of disease progression.^[39]

Common metastatic sites and hospice implications:

Bone (90%): Osteoblastic. Axial skeleton predominant (spine, pelvis, ribs). SREs in 40%+ of patients: fractures, spinal cord compression, bone pain requiring RT, hypercalcemia.
Lymph nodes (25–35%): Pelvic nodal disease causes ureteral obstruction, lower extremity lymphedema, bowel compression.
Bladder/Prostate local (15–25%): Urinary outlet obstruction, hematuria, fistula formation.
Lung (15–20%): Usually parenchymal; lymphangitic spread causes dyspnea.
Brain (<5%): More common in CRPC after multiple lines; seizures, cognitive changes, focal deficits.
Liver (10–15%): Late-stage finding; associated with rapid functional decline and poor prognosis.

🧭 Clinical framing

Prostate cancer is not just a fatal cancer — it is a long, slow dismantling of masculine identity, physical autonomy, and sexual function. By the time a patient reaches hospice, he has often been fighting this disease for years. Bone pain, urinary failure, and hormonal symptoms define the clinical picture. The hospice team walks into a room where a man has been losing pieces of himself for a long time.

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"This disease doesn't kill fast — it dismantles. By the time these men reach us, they've been on hormones for years. They've lost their sex life, their muscle mass, their independence — piece by piece. And most of them never said a word about it because nobody asked. Don't walk in and start with the pain scale. Start with: 'How are you really doing?' And then sit there long enough for the real answer. The bone pain is terrible, yes — but the undertreated thing in prostate cancer isn't the bones. It's the man."

— Waldo, NP · Terminal2

S02Clinician

How It's Diagnosed

Diagnostic workup, staging, and what to look for in hospice records. Most patients arrive with an established diagnosis — this section helps you read it.

Diagnostic Workup

PSA: Screening and monitoring marker — not diagnostic alone. Rising PSA velocity (>2 ng/mL/year) is concerning. In hospice, PSA trend tracks disease acceleration.
Biopsy: TRUS biopsy or MRI-fusion biopsy confirms diagnosis. Gleason score / Grade Group system (1–5) determines aggressiveness.
Staging: CT chest/abdomen/pelvis, bone scan, or PSMA-PET for staging. PSMA-PET is increasingly standard and more sensitive than conventional bone scan.
Molecular testing: AR-V7 (predicts resistance to enzalutamide/abiraterone), BRCA1/2 (olaparib eligibility), MSI-H/dMMR (pembrolizumab eligibility).^[16]

What to Look for in Hospice Records

PSA trend: Rapidly rising PSA = accelerating disease. PSA doubling time <3 months is a poor prognostic sign.
BRCA status: If tested — olaparib eligibility and family counseling implications for daughters and sons.
AR-V7 status: If positive, enzalutamide/abiraterone unlikely to benefit — guides hospice goals discussion.
Prior radiation fields: Irradiated spine behaves differently — re-irradiation dose constraints matter for SCC management.
Bone met locations and load: Spine mets + neurological symptoms = SCC emergency. Know the map.
Catheter/urinary diversion status: Foley, suprapubic, nephrostomy — each has different management needs.
Prior bisphosphonate/denosumab use: ONJ risk from prolonged bone-modifying agents.

📋 Staging progression

Localized → locally advanced → metastatic hormone-sensitive (mHSPC) → metastatic castration-resistant (mCRPC). mCRPC is defined by PSA progression despite castrate testosterone levels (<50 ng/dL). This transition — from hormone-sensitive to castration-resistant — is the clinical inflection point that typically precedes hospice enrollment.

💡 For families

Most diagnostic workup is already complete by the time hospice begins. The tests, biopsies, and scans that identified his cancer have been done. The focus now is entirely on comfort — not on more testing, but on making every day as good as it can be.

S03Everyone

Causes & Risk Factors

Modifiable and hereditary risk factors. Relevant for family conversations, genetic counseling referrals, and answering "why did this happen?"

Modifiable Risk Factors

High-fat diet: Associated with increased prostate cancer risk and aggressive disease in observational studies.
Obesity: Higher BMI correlates with more aggressive prostate cancer at diagnosis and worse outcomes.
Agent Orange exposure: VA-recognized service-connected condition — flag for veteran patients. Qualifies for VA disability benefits and concurrent care.^[7]

Hereditary & Non-Modifiable

Age: Most common cancer in men >65. Risk increases significantly with each decade after 50.
Family history: First-degree relative with prostate cancer doubles risk. Two or more first-degree relatives — 5–11x risk.
BRCA2: 3–8x increased risk of prostate cancer — the most significant hereditary factor. Associated with earlier onset and more aggressive disease.
BRCA1: Moderately increased risk (~1.8x). Less well-defined than BRCA2 but clinically relevant.
Lynch syndrome (MSI-H): Increased prostate cancer risk; pembrolizumab eligibility if dMMR/MSI-H.
African American race: Significantly higher incidence AND mortality — the largest racial disparity of any cancer in the US.

❤️ For families: "Why did this happen?"

This is one of the most common questions families ask. Prostate cancer develops from a combination of age, genetics, and factors no one could have controlled. It was not caused by something he did or didn't do. Some families carry a genetic risk — if BRCA2 has been identified, this affects your family's cancer screening too. But right now, the most important thing is not why it happened — it's what we do together from here.

⚕ Clinician note: Racial disparity

Black men have 70% higher incidence of prostate cancer and more than twice the mortality rate of white men — this is the largest racial disparity of any cancer in the US. It is not explained by biology alone. Screening disparities, healthcare access, and systemic factors contribute. When you walk into the home of a Black man dying of prostate cancer, you are walking into the downstream consequence of decades of systemic failure. Do not let it continue at the bedside — assess pain without assumptions, prescribe without bias.

⚕ Clinician note: Genetic counseling

BRCA2 mutations affect daughters and sons — they significantly increase breast, ovarian, prostate, and pancreatic cancer risk in family members. Genetic counseling referral is appropriate even at hospice enrollment. Identifying a BRCA2 mutation in a dying father can save the lives of his children through enhanced screening and risk-reduction strategies. Ask about family cancer history; refer when indicated.

S04ClinicianEveryone

Treatments & Procedures

What disease-directed treatments this patient may have received or may still be receiving. Understanding prior therapy helps anticipate complications and interpret the patient's trajectory.

Prostate cancer treatment is sequential and prolonged. Unlike most solid tumors, men with metastatic prostate cancer may receive 4–6 lines of systemic therapy over several years before reaching hospice. Each line leaves a footprint — hormonal, metabolic, hematologic, and psychological — that the hospice team must understand and manage. Know what's been done: hormonal therapies leave a permanent endocrine footprint that affects symptom management at every stage.^[39]

Systemic Therapies

ADT / Castration: LHRH agonists (leuprolide, goserelin), LHRH antagonists (degarelix, relugolix), or bilateral orchiectomy. Foundation of all prostate cancer treatment.
First-gen antiandrogens: Bicalutamide — older agent, still used as flare protection or combined androgen blockade.
Second-gen ARSIs: Enzalutamide, abiraterone (+ prednisone), darolutamide, apalutamide — oral, well-tolerated, significant OS benefit in mHSPC and mCRPC.^[19]
Chemotherapy: Docetaxel (first-line chemo), cabazitaxel (post-docetaxel). Myelosuppression, neuropathy, fatigue.
PARP inhibitors: Olaparib, rucaparib — for BRCA1/2-mutant mCRPC. Oral, targeted, ~30% response.
Radioligand therapy: Lu-177 PSMA (Pluvicto) — for PSMA-positive mCRPC post-ARSI and docetaxel (VISION trial).
Bone-targeted: Zoledronic acid (IV), denosumab (SQ) — reduce SREs. Radium-223 (Xofigo) — alpha-emitter with OS benefit in bone-dominant mCRPC.^[24]

Palliative Procedures

Urinary catheterization: Indwelling Foley or suprapubic catheter for bladder outlet obstruction — the most common palliative procedure in prostate cancer hospice.
Ureteral stent / nephrostomy: For bilateral ureteral obstruction from pelvic nodes. Goals discussion essential before placing.
Palliative RT for bone pain: Single fraction 8 Gy — equivalent pain control to multi-fraction, preferred near end of life, underused in practice.^[31]
SRS for spinal mets: Stereotactic radiosurgery for limited spinal disease — high-dose, precise, single session.
Kyphoplasty / vertebroplasty: Cement stabilization for painful vertebral compression fractures. Can provide rapid pain relief.
Palliative TURP / HoLEP: Transurethral resection or laser enucleation for obstructing prostate tissue — rapid symptom relief.^[50]

S05Clinician

When Therapy Makes Sense

Evidence-based criteria for continuing disease-directed therapy. This is not about giving up or holding on — it's about reading the data correctly.

Unlike most cancers, prostate cancer often has legitimate sequential therapy options extending years — the transition from treatment to hospice is rarely abrupt and requires careful framing. Palliative care consultation earlier in this trajectory reduces aggressive EOL care and improves quality of life.^[1]

01
mHSPC with docetaxel + ADT or triplet therapy (ECOG 0–2): Significant OS benefit with modern combination approaches. These patients are not hospice candidates — they have years of meaningful disease control ahead.
02
mCRPC with enzalutamide or abiraterone as first ARSI: Oral, well-tolerated, meaningful OS benefit (median 13–18 months). Low toxicity profile makes these compatible with comfort goals in many patients.^[19]
03
BRCA-mutant mCRPC with olaparib: Oral, targeted, ~30% response rate. Well-tolerated. PARP inhibitors offer meaningful disease control in molecularly selected patients.
04
MSI-H with pembrolizumab: Rare (~3–5% of mCRPC) but meaningful responses when present. Immunotherapy can produce durable responses in selected patients.
05
Lu-177 PSMA in PSMA-positive mCRPC post-ARSI and docetaxel: VISION trial demonstrated OS benefit (15.3 vs 11.3 months). Requires PSMA-PET positivity. IV therapy — clinic visits required.
06
Radium-223 for bone-dominant mCRPC without visceral mets: ALSYMPCA trial — OS benefit, SRE reduction, pain improvement. Alpha-emitter with manageable toxicity.^[24]
07
Patient goals explicitly include life-prolongation with full prognosis understanding: A well-informed patient who understands prognosis and chooses active treatment should receive it without judgment.

S06Clinician

When It Doesn't

Knowing when treatment stops helping is not clinical failure. It is the most important clinical skill in this disease.

Prostate cancer's slow trajectory creates systematic delays in hospice referral. In one population-based study, 80% of prostate cancer patients died in hospital, with palliative care initiated a median of only 27 days before death — far too late.^[30] The long treatment history convinces patients, families, and sometimes oncologists that there is always "one more thing to try."

01
ECOG ≥3: No evidence of benefit from chemotherapy or most systemic therapy at this performance status. Toxicity increases, benefit disappears.
02
Progression through ≥2 ARSI agents: Cross-resistance between enzalutamide and abiraterone is common. Sequential ARSIs after first failure rarely produce meaningful responses.
03
Post-docetaxel and cabazitaxel without actionable molecular target: Without BRCA, MSI-H, or PSMA positivity, remaining options offer marginal benefit at significant toxicity cost.
04
Visceral crisis: Hepatic replacement or pulmonary lymphangitic carcinomatosis — median survival weeks, not months. Aggressive therapy causes more suffering than benefit.
05
Rapidly rising PSA with symptomatic progression despite all lines: When every class of agent has been tried and disease accelerates, the data is clear.
06
Estimated survival <6 months: Hospice enrollment is appropriate, beneficial, and guideline-supported. All thresholds above converge here.
07
Patient goals shift to comfort and home time: When a fully informed patient prioritizes quality over quantity, that is not giving up. It is clarity.

📋 Clinician note

Prostate cancer patients and families often feel there is always "one more thing to try" because the treatment history is so long. The question is not whether options exist on paper — it's whether those options will add comfortable time or only add hospital visits, toxicity, and false hope. Name that directly.

S07Everyone

Out-of-the-Box Approaches

Evidence-graded integrative, interventional, and complementary approaches. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.

Palliative Radiation for Bone Pain

Grade A

Dose: Single-fraction 8 Gy to painful site

Equivalent pain control to multi-fraction regimens for uncomplicated bone pain. Preferred near end of life — one visit, one treatment. Underused in practice: most centers still prescribe 10-fraction courses by default. Response onset 2–4 weeks; plan analgesics to cover the interval. Re-irradiation is safe at previously treated sites.^[31]^[32]

Resistance Training for ADT Side Effects

Grade A

Dose: 2–3×/week, adapted to functional capacity

Combined resistance/aerobic exercise is the strongest non-pharmacological intervention for ADT-related fatigue, muscle loss, and cardiovascular risk — improves fitness without elevating testosterone. Cochrane-level evidence. In hospice: tailor to function — chair exercises, gentle walking, stretching all provide benefit and dignity.^[46]

Acupuncture

Grade B

Dose: 1–2 sessions/week, 20–30 min per session

Multiple RCTs in prostate cancer show benefit for bone pain, hot flashes, and cancer-related fatigue. Acupuncture for ADT-induced hot flashes has specific RCT support. Safe in hospice — no drug interactions. Practical barrier: requires trained practitioner access.

Mind-Body / MBSR

Grade B

Dose: Daily practice, 15–45 min; group programs 8 weeks

Prostate cancer-specific mindfulness data shows improvement in anxiety, depression, fatigue, and QoL. Particularly beneficial for men processing loss of identity and autonomy. Can be adapted for bedbound patients — guided audio, breathing exercises.

Massage

Grade B

Dose: 20–60 min, 1–3×/week as tolerated

Reduces pain, anxiety, and improves sleep in cancer patients. Gentle massage safe in patients with bone mets — avoid direct pressure on known met sites. Can be taught to family caregivers for comfort touch.

Radium-223 Discussion

Grade A

Dose: 55 kBq/kg IV q4 weeks × 6 cycles

ALSYMPCA trial: OS benefit (14.9 vs 11.3 mo), SRE reduction, pain improvement. Alpha-emitter for bone-dominant mCRPC without visceral mets. Minimal myelosuppression. May be appropriate to discuss continuation for patients entering hospice mid-cycle — VA concurrent care may allow continuation.^[24]^[25]

S08Everyone

Natural & Herbal Options

Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to prostate cancer. Patients will use supplements — this section helps you have the right conversation.

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"Patients are going to use supplements whether we ask or not. The conversation is: 'I want to know what you're taking — not to judge you, but because some of these interact with your pain medications and blood thinners.' Say it plainly. Most of the time they're relieved someone asked."

— Waldo, NP

Herb / Supplement	Evidence Grade	Typical Dose	Potential Benefit	⚠ Interactions / Contraindications
Saw Palmetto	Grade C	320 mg/day standardized extract	Urinary symptom (LUTS) relief — some men report benefit though RCTs are mixed^[55]	Mild antiplatelet activity; mild CYP interaction. Mild anti-androgenic properties — theoretical interference with ADT at high doses (low clinical significance at standard doses).
Lycopene	Grade C	15–30 mg/day from food sources preferred	Antioxidant; prevention signal in observational data. Meta-analysis of 6 RCTs: no significant PSA effect.^[53]	May mildly enhance anticoagulant effects (warfarin). Safe at dietary doses. Avoid mega-doses (>75 mg/day).
Green Tea / EGCG	Grade C	2–3 cups or 300–600 mg EGCG/day	Anti-androgenic preclinical signal; antioxidant properties^[58]	CYP3A4 interactions (enzalutamide, abiraterone, docetaxel — monitor). Antiplatelet effect. Hepatotoxicity at high supplemental doses. Caffeine worsens LUTS — use decaf.
Pomegranate Juice	Grade D	8 oz/day	Popular in prostate cancer community; weak PSA data from small uncontrolled studies	Generally safe. No significant drug interactions at dietary doses. Sugar content a consideration in diabetic patients.
Ginger	Grade B	1 g/day in divided doses	Nausea relief — chemotherapy-related and general cancer nausea. Multiple positive RCTs.	Generally safe. Mild antiplatelet activity at high doses. No significant CYP interactions at standard doses.

🚫 Avoid in Prostate Cancer

High-dose zinc: Paradoxically associated with increased prostate cancer risk in observational studies. Avoid supplementation above RDA (11 mg/day).
DHEA and testosterone supplements: Androgenic — fuels prostate cancer growth. Absolutely contraindicated in any patient with prostate cancer, active or history.
High-dose selenium: SELECT trial (n=35,533): no benefit, possible harm. Vitamin E supplementation significantly increased prostate cancer risk.^[57]
St. John's Wort: Major CYP3A4 inducer — destroys enzalutamide and abiraterone levels. SERIOUS and COMMON interaction. Screen for this at every visit.
Ginkgo and high-dose fish oil: Antiplatelet effects — bleeding risk in patients on anticoagulation or with thrombocytopenia from bone marrow involvement.

S09Everyone

Timeline Guide

A guide, not a prediction. Prostate cancer has the longest and most variable trajectory of any cancer in hospice. Every patient's path is shaped by prior treatments, molecular profile, and treatment response.

YRS–
MOS

Localized or mHSPC on ADT

PSA controlled, functional, living relatively normally with cancer
Hot flashes, sexual dysfunction, fatigue from ADT accumulating from day one
Bone mineral density declining — osteoporosis developing silently
This phase can last years — some men live a decade with metastatic hormone-sensitive disease
Early palliative care integration is critical — advance care planning, establishing relationships, normalizing the conversation

MOS–
1 YR

mCRPC Developing — Second-Gen ARSI Era

PSA rising despite castrate testosterone — castration resistance emerging
Enzalutamide, abiraterone, or newer ARSI initiated — often effective for months to over a year
Bone pain emerging — first skeletal-related events may occur
Hospice concept should be introduced — not as imminent, but as a future resource
This is the window for goals-of-care conversation framing^[14]

WKS–
MOS

Post-ARSI / Post-Docetaxel Progression — Hospice Window

Progression through second-line therapy — response rates declining, toxicity accumulating
Regular opioids for bone pain — ATC dosing becoming necessary
Urinary symptoms worsening — catheter may be placed
ECOG 2–3 — increasing dependence, declining function
This is the hospice enrollment window — do not wait for ECOG 4

DAYS–
WKS

Active Dying — Pre-Active Phase

Bed-bound, ATC opioids, catheter in place
Possible hypercalcemia — confusion, nausea, somnolence
SCC risk peaks — new back pain with leg symptoms requires immediate dexamethasone
Profound fatigue — sleeping most of day, minimal oral intake
Family education critical: what to expect, what is normal, when to call

HRS–
DAYS

Final Hours

Cheyne-Stokes or agonal breathing; mandibular movement; mottling of knees and feet
Unresponsive or minimally responsive — auditory awareness may persist
Discontinue all non-comfort medications — focus entirely on symptom management
Glycopyrrolate for secretions, midazolam for agitation, morphine for pain/dyspnea
Family presence is the priority — create space, lower voices, give permission

S10Clinician

Medications to Anticipate

Symptom-targeted pharmacology for prostate cancer. What to have in the comfort kit, what to titrate first, and what the evidence supports.

Bone pain is the dominant symptom driving medication decisions in prostate cancer hospice. In a real-world European cohort, 70% of patients with bone mets had active bone pain, and 97% were on analgesics — yet 28% reported moderate to severe pain despite treatment, suggesting systematic underdosing.^[20] Osteoblastic lesions generate a distinct pain mechanism: periosteal nerve stimulation, bone marrow edema, and microstructural collapse under weight-bearing. Treat the patient, not the scan.

Drug	Class / Target Symptom	Starting Dose	Notes / Cautions
Morphine / Oxycodone	Opioid / Bone Pain	5–10 mg PO q4h	Osteoblastic lesions are mechanically weak and intensely painful. Titrate rapidly — don't leave on inadequate dose. IR for breakthrough, ER for baseline. Convert to SQ if swallowing fails.^[20]
Dexamethasone	Corticosteroid / SCC Emergency	10 mg IV/SQ stat	Immediate on any suspicion of SCC. Also used as pain adjunct, appetite stimulant, and anti-emetic. Maintenance 4–8 mg daily for bone pain flare. ⚠ Monitor glucose, GI protection with PPI^[36]
Zoledronic acid / Denosumab	Bone-Modifying / Fracture Prevention	ZA 4 mg IV q4wk; Denosumab 120 mg SQ q4wk	Continue in hospice if reducing SREs and patient tolerating. Denosumab preferred if renal impairment (no CrCl threshold). ONJ risk — dental assessment.^[17]
Gabapentin / Pregabalin	Neuropathic / Radiculopathy	Gabapentin 100–300 mg TID, titrate	For vertebral compression neuropathy, CIPN, SCC-related neuropathic pain. Renal dose adjustment essential. Pregabalin 75 mg BID as alternative.
NSAIDs	Anti-inflammatory / Bone Pain Adjunct	Ibuprofen 400–800 mg TID	Prostaglandin-mediated bone pain responds to NSAIDs as opioid adjunct. GI protection with PPI. Avoid if CrCl <30 or bleeding risk.
Leuprolide / ADT continuation	Hormonal / Disease Control	Individualize	Some benefit from continued castration even in mCRPC. Weigh against ADT side effects. Discuss with patient: simplification of care vs. continued control.^[39]
Cyproterone / Megestrol	Progestational / Hot Flashes	Cyproterone 50 mg daily; Megestrol 20 mg daily	For severe hot flashes refractory to venlafaxine/gabapentin. Comfort-focused use in hospice — progestational activity accepted in terminal context.
Tamsulosin / Terazosin	Alpha-blocker / Urinary Obstruction	Tamsulosin 0.4 mg qHS; Terazosin 1–2 mg qHS	Relaxes bladder neck smooth muscle. Reduces urinary hesitancy, urgency, incomplete emptying. Monitor orthostatic hypotension, especially with opioids.
Lorazepam	Benzodiazepine / Anxiety	0.5–1 mg PO/SQ q4–6h PRN	Adjunctive for anxiety component. Useful for dyspnea-related anxiety. Avoid scheduled use unless breakthrough frequent.
Midazolam	Benzodiazepine / Terminal Agitation	2.5–5 mg SQ PRN	Terminal agitation and catastrophic symptom management. Have in comfort kit drawn and labeled. Can give as CSCI 10–30 mg/24h for refractory agitation.
Glycopyrrolate	Anticholinergic / Terminal Secretions	0.2 mg SQ q4h	Reduces secretions without CNS effects. Preferred over hyoscine in conscious patients. Family education: "This sound is not distressing to your loved one."

🌿 Symptom Management Decision Tree

Evidence-based · Hospice-adapted

Select a symptom below to begin

What is the primary symptom to address?

🚨 SCC Emergency Protocol — Comfort Kit Must-Have

For patients with vertebral bone mets — spinal cord compression is a medical emergency even in comfort-focused care. New or worsening back pain + leg weakness or numbness + any bowel or bladder change = call immediately. Dexamethasone 10 mg SQ/IM immediately while arranging urgent assessment. Have this conversation with the family explicitly before it happens — write it in the care plan. Pre-draw dexamethasone and label it in the comfort kit. The difference between walking and paralysis is measured in hours, not days.

S11Clinician

Clinician Pointers

High-yield clinical pearls for the hospice team. The things not in the textbook — learned at the bedside over years of clinical experience.

Osteoblastic bone mets look dense but are mechanically weak

Imaging shows "sclerotic" lesions that appear solid — but these bones are brittle and fracture-prone. Pain is undertreated because scans look stable. Treat the patient's report, not the imaging appearance. Incident pain with movement is the hallmark — optimize opioid dosing for activity-related spikes.

SCC is THE emergency — prepare before it happens

Know the spine met locations from imaging. Teach the family warning signs: new back pain + leg weakness + any bowel or bladder change. Have dexamethasone in the comfort kit. Write the protocol in the care plan. Have the conversation explicitly — "If this happens, here's what we do." The window between ambulatory and paraplegic is hours.^[33]

Urinary obstruction develops gradually — assess every visit

Check urine output character and volume at every visit. Post-void residual increases silently. By the time a patient is in retention, he's been struggling for weeks without mentioning it. Proactive assessment prevents urosepsis and emergency catheterization. Ask directly: "How is your urine stream?"

ADT hormonal footprint persists into hospice

Hot flashes, gynecomastia, emotional lability, osteoporosis — these are treatment effects, not disease progression. They persist for the duration of hospice. Manage actively: venlafaxine or gabapentin for hot flashes, normalize emotional changes, fall prevention for osteoporotic bones.^[40]

Men with prostate cancer rarely ask for psychological help

Screen actively, not passively. Depression, anxiety, and existential distress are undertreated in this population because men don't volunteer symptoms. Use direct screening questions at every visit: "Are you depressed?" has 100% sensitivity in terminally ill men. Don't wait for him to bring it up — he won't.^[9]

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"A lot of these men grew up being told that real men don't ask for help. But they'll accept it if you frame it right. Not 'we can't do anything more for you' — instead: 'We're going to throw everything we have at keeping you comfortable, at home, in control, on your terms.' That's not giving up. That's fighting on different ground."

— Waldo, NP · Terminal2

S12EveryoneClinician

Psychosocial & Spiritual Care

Existential distress, depression screening, spiritual assessment, and goals-of-care communication. The symptom burden you can't see on a vitals sheet.

Prostate cancer uniquely threatens masculine identity: loss of sexual function, urinary incontinence, gynecomastia, and body hair loss — all caused by treatment — can profoundly undermine how men see themselves. Depression, anxiety, and existential distress are underdiagnosed in this population, particularly in men who have learned stoicism and self-reliance as core values. Psychosocial distress in prostate cancer is as clinically significant as bone pain — and far more likely to go unaddressed.

Psychological Distress Screening

Depression — Screen Every Patient

Grade B

Single-question screen: "Are you depressed?" has 100% sensitivity in terminally ill populations when phrased directly.

PHQ-2: "Little interest/pleasure" + "Feeling down/hopeless" — score ≥3 warrants full PHQ-9
Mirtazapine 7.5 mg QHS: First-line in hospice — addresses depression, insomnia, and anorexia simultaneously
Distinguish depression from appropriate sadness — both deserve attention; only one warrants pharmacotherapy
Men with prostate cancer underreport depressive symptoms — use validated tools, don't rely on self-report

Anxiety & Existential Distress

Grade B

Distinguish anxiety subtypes: Situational, generalized, existential, death anxiety — each responds differently
Lorazepam 0.5 mg PRN for acute anxiety episodes — avoid scheduled use unless breakthrough frequent
Dignity therapy: Structured life narrative intervention — reduces suffering and increases sense of meaning
Loss of autonomy (urinary, sexual, functional) drives existential distress uniquely in prostate cancer^[9]
Refer to social work and chaplain at enrollment — not at crisis

Spirituality in Prostate Cancer

In a study of disadvantaged men dying of prostate cancer, those with higher spirituality scores trended toward greater hospice enrollment (33% vs 13%) and more palliative radiation use.^[3] Higher spirituality was associated with redirecting care from curative to palliative goals — faith as a facilitator of comfort-focused care, not a barrier. Spirituality is not the same as religion. Patients with no religious affiliation still have spiritual needs — meaning, legacy, connection, peace. Use the FICA framework: Faith/beliefs, Importance, Community, Address.

Clinical Pearl

"What gives you strength during this time?" opens spiritual conversation without assuming religion. For men of faith, framing hospice as "continuing to fight — just with different weapons" may resonate more than any clinical argument about prognosis.

Suicidal Ideation & Hastened Death Requests

End-of-life desire for hastened death and suicidal ideation occur in patients with advanced prostate cancer, driven by intractable pain, loss of autonomy (urinary, sexual, functional), existential suffering, and depression.^[9] Assessment requires careful distinction: passive wish for death ("I'm ready to go" — common, often existentially appropriate), active suicidal ideation with plan (requires immediate psychiatric engagement), and medical aid in dying requests (legal in some jurisdictions — requires specific protocol). Do not conflate these. Do not avoid the question.

Masculine Identity & Communication

01
Ask about faith community explicitly: "Is there a faith community or spiritual leader who should know you're ill?" Don't assume — patients often won't volunteer without being asked.^[3]
02
Involve chaplaincy at enrollment: Spiritual care is a clinical discipline. Chaplains are the experts. Your job is to open the door — theirs is to walk through it.
03
Address sexual health directly — normalize the question: "Some men on these medications find their sex life has changed — is that something we should talk about?" Many men won't ask. The loss is profound and silent.
04
Frame hospice around control — staying home, on his terms: Not "we can't do anything more" but "we're going to fight to keep you comfortable, at home, in control." Shared decision-making restores agency.
05
Veteran-specific: Validate service. Connect to VA resources. Understand that "mission completion" framing may resonate — "You've served your country. Let us serve you." Agent Orange status qualifies for VA benefits.^[7]

Goals-of-Care Communication

Opening the Conversation

"What is your understanding of where things stand with your illness?" — assesses illness understanding before prognostic disclosure
"What are you hoping for?" — surfaces values, not just preferences
"What are you most afraid of?" — identifies what goals-of-care planning must address
"If things got worse, what would matter most to you?" — elicits priorities without triggering defensiveness

Communication Pitfalls

Don't use language of surrender: "Stopping treatment" vs "shifting the focus of care"
Don't say "there's nothing more we can do": There is always more to do — it just looks different now
Don't conflate hospice with giving up: Frame around what hospice adds, not what it ends
Don't have this conversation standing up: Sit down. Make eye contact. Leave silence.
Involve the family separately when needed: Patients and families often have different goals

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"I've sat with patients who were profoundly at peace and patients who were in spiritual agony — and from the outside, you couldn't always tell the difference. The ones in agony weren't always crying. Some of them were very quiet, very polite, very 'I'm fine.' You have to ask. You have to ask directly, you have to sit down, and you have to mean it when you do."

— Waldo, NP · Terminal2

S12FamilyEveryone

Family Guide

Plain language for families. Share, print, or read aloud at the bedside.

If you are reading this, someone you love has advanced prostate cancer — and you are part of his care team now. This disease has likely been part of your lives for a long time already. The treatments, the doctor visits, the side effects, the worry — you have carried all of that alongside him. What comes next is different, but your role is just as important. This guide will help you understand what you may see and how you can help.

What You May See

Severe bone pain (back, hips, pelvis): This is the most common symptom. He may wince with movement, resist getting out of bed, or guard certain positions. Pain medications can control this — tell the nurse if he seems uncomfortable.
Difficulty walking or leg weakness: This can be a sign of spinal cord compression — report immediately. New back pain with leg weakness or numbness needs urgent attention.
Urinary changes or catheter: A catheter may be placed to help drain urine. This is normal and keeps him comfortable. Keep the bag below body level and empty when half full.
Extreme fatigue and sleeping more: This is expected. His body is conserving energy. Let him rest — don't try to keep him awake.
Hot flashes and sweating: This is from the hormone medication, not a fever. Cool cloths, a fan, and lightweight clothing help.
Emotional withdrawal or quietness: Many men process this inwardly. He may not talk about how he feels. That doesn't mean he doesn't need you there.

How You Can Help

Don't minimize his pain: If he says he hurts, believe him. Men often underreport — if he's saying it, it's real.
Help with catheter care: The nurse will teach you. Keep drainage bag below body level, empty regularly, watch for changes in color or output.
Watch for and report back pain with leg weakness: This combination needs an immediate call to the nurse — write it on the fridge.
Create space to talk without fixing: You don't need to have answers. Sitting with him, holding his hand, being present in the silence — that's enough.
Frame care around his control: Let him make choices where he can — what to eat, who to see, where to sit. Control over small things matters enormously.
Take care of yourself: Caregiver exhaustion is real. Call the hospice team when you need support — not just when he does.

📞 Call the nurse immediately if you see:

New sudden back pain with leg weakness or numbness — this could be spinal cord compression and needs immediate attention. Inability to urinate despite catheter — may indicate catheter blockage or malfunction. Sudden confusion or agitation — could indicate hypercalcemia, infection, or medication issue. Inability to be woken — if this is a sudden change from his baseline, call immediately.

🙏 Caring for a man who has spent years fighting this disease and rarely asked for help is one of the most demanding caregiving roles in hospice. What you are doing is extraordinary. Your presence — your willingness to be there when he finally lets you — is the most therapeutic thing available. You are not failing him. You are fighting alongside him on different ground.

S14Everyone

Waldo's Top 10 Tips

Clinical field wisdom from 12+ years at the bedside. The things you learn after doing this long enough. Not guidelines — real.

01
Bone pain is undertreated in prostate cancer. Every single time. Osteoblastic lesions look stable on a scan — dense, sclerotic, "nothing new." But those bones are brittle and the man is in agony. He's not reporting it because he's been told to be tough his whole life, and he figures this is just what cancer feels like. It's not. Treat the patient, not the scan. Ask specifically about positional pain, incident pain with movement, and nighttime pain that breaks through sleep. If he's using more than 3 PRN doses a day, his baseline is wrong. Fix it.
02
SCC preparedness is not optional — it's your job. Before it happens. Know where his spine mets are from the last imaging. Have the dexamethasone conversation with the family: "If he develops new back pain with leg weakness, this is what we do." Write it in the care plan. Pre-draw the dexamethasone and label it. Put the protocol on the fridge. The difference between a man who walks and a man who doesn't is whether someone recognized SCC in the first 12 hours.
03
The masculine identity conversation — you have to open the door because he won't. Ask about sexual function. Ask about incontinence. Ask about body changes — the gynecomastia, the muscle loss, the weight he's gained in places he's never carried weight before. These men have lost pieces of themselves that defined who they were. Nobody asked because it felt awkward. It's more awkward to die with those things unspoken. Open the door. You don't have to walk through it — just open it.
04
Stoicism kills. Literally. Men die with undertreated depression, undertreated anxiety, and undertreated pain in prostate cancer because they don't report symptoms and we don't ask hard enough. "I'm fine" is not an assessment — it's a deflection. Use direct screening tools at every visit. "Are you depressed?" is a validated question with 100% sensitivity in terminally ill men. Ask it. Then sit there. The silence is where the truth lives.
05
ADT side effects don't stop when hospice starts. Hot flashes, gynecomastia, emotional lability, osteoporosis — these are treatment effects that persist for the duration of his life. Don't dismiss them as "just the hormones." Manage them actively: venlafaxine or gabapentin for hot flashes, normalize the emotional changes with the family, fall prevention for the osteoporotic bones. These symptoms are treatable and they're making his remaining time worse.
06
Check the catheter — output character and volume — at every single visit. Urinary obstruction develops gradually in prostate cancer. The man adapts to reduced flow, increased frequency, nighttime waking. By the time he's in acute retention, he's been struggling for weeks. Proactive assessment — checking post-void residual, asking about stream quality, watching output volume — prevents the 2 AM emergency catheterization that nobody wants.
07
Racial disparity in prostate cancer pain management is documented and it's your problem to fix. Black men are more likely to have pain undertreated, opioids underprescribed, and symptoms minimized. This is not opinion — it's data. You are the correction. Assess pain without assumptions. Prescribe without bias. If your patient is a Black man dying of prostate cancer, you are standing at the end of a long chain of systemic failure. Don't add another link.
08
If your patient is a veteran, learn the language. Agent Orange exposure is a VA-recognized risk factor for prostate cancer — it qualifies for disability benefits and concurrent care. Veterans respond to mission-completion framing: "You've served your country — let us serve you." VA concurrent care allows hospice plus disease-modifying treatment simultaneously — the only payer that does this without the "terrible choice." Know the resources. Use them.
09
The "one more treatment" conversation is the hardest in prostate cancer because it's not irrational. This man has been through 4, 5, 6 lines of therapy. Each one worked for a while. His family has watched treatments succeed before. So when you say "there's nothing more that will help," they don't believe you — because they've been here before and something always came next. Be honest about what more treatment offers at this stage: not more time, but more hospital visits, more toxicity, and less time at home. Name it directly.
10
Caregiver partners in prostate cancer — usually female spouses — carry an enormous invisible burden. They've watched him lose his sex drive, his muscle, his independence. They've managed side effects that nobody talked about openly. They've been strong while he was stoic. By the time hospice arrives, she's exhausted and nobody has assessed her directly. Do it. At every visit. "How are YOU doing?" is not a courtesy — it's clinical care. She's part of the treatment team whether she knows it or not.

— Waldo, NP

REFClinician

References

62 peer-reviewed citations from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.

Triplett DP, et al. Effect of Palliative Care on Aggressiveness of End-of-Life Care Among Patients With Advanced Cancer. J Oncol Pract. 2017;13(9):e760–e769.

PMID 28829693 DOIObservational

Haltia O, et al. The indirect costs of palliative care in end-stage cancer: a real-life longitudinal register- and questionnaire-based study. Palliat Med. 2018;32(2):493–499.

PMID 28895471 DOIObservational

Bergman J, et al. Spirituality and end-of-life care in disadvantaged men dying of prostate cancer. World J Urol. 2011;29(1):43–49.

PMID 21170717 DOIObservational

Cullen G. End-of-Life Care: Use of Antineoplastic Therapy and Nonessential Medications in Veteran Patients Receiving Palliative Care. Clin J Oncol Nurs. 2020;24(6):667–672.

PMID 33216053 DOIObservational

Mast KR, et al. End-of-life content in treatment guidelines for life-limiting diseases. J Palliat Med. 2004;7(6):754–773.

PMID 15684843 DOIReview

Wu JN, Meyers FJ, Evans CP. Palliative care in urology. Surg Clin North Am. 2011;91(2):429–444.

PMID 21419262 DOIReview

Mor V, et al. The rise of concurrent care for veterans with advanced cancer at the end of life. Cancer. 2016;122(5):782–790.

PMID 26670795 DOIObservational

Färkkila N, et al. Health-related quality of life among breast, prostate, and colorectal cancer patients with end-stage disease. Qual Life Res. 2014;23(4):1387–1394.

PMID 24178630 DOIObservational

Calagua-Bedoya EA, et al. Suicidal Ideation in a Patient at the End-of-Life (advanced prostate cancer). J Acad Consult Liaison Psychiatry. 2023;64(4):371–382.

PMID 36494065 DOIReview

Skov Benthien K, et al. Is specialized palliative cancer care associated with use of antineoplastic treatment at the end of life? Palliat Med. 2018;32(9):1509–1517.

PMID 30004303 DOIObservational

Blaschke K, et al. Cancer Patients and the Last Year of Life: Palliative Care, Hospitalization and Place of Death. Gesundheitswesen. 2020;82(8–09):702–709.

PMID 30974465 DOIObservational

Yeung HN, et al. Palliative radiation before hospice: the long and the short of it. J Pain Symptom Manage. 2014;48(6):1070–1079.

PMID 24819083 DOIObservational

Wang H, et al. Rural-Urban Differences in Costs of End-of-Life Care for Elderly Cancer Patients in the United States. J Rural Health. 2016;32(4):353–362.

PMID 26586101 DOIObservational

Collins A, et al. Transition Points for the Routine Integration of Palliative Care in Patients With Advanced Cancer. J Pain Symptom Manage. 2018;56(2):185–194.

PMID 29608934 DOIObservational

Ellsworth SG, et al. Patterns of care among patients receiving radiation therapy for bone metastases at a large academic institution. Int J Radiat Oncol Biol Phys. 2014;89(5):1100–1105.

PMID 25035214 DOIObservational

Crawford ED, Stanton W, Mandair D. Darolutamide: an Evidence-Based Review of Its Efficacy and Safety in Prostate Cancer. Cancer Manag Res. 2020;12:5667–5676.

PMID 32765070 DOIReview

Kuppen MCP, et al. Symptomatic Skeletal Events and the Use of Bone Health Agents in Real-World Treated mCRPC: CAPRI-Study. Clin Genitourin Cancer. 2022;20(1):43–52.

PMID 34848157 DOIObservational

Uemura H, et al. Treatment patterns of mCRPC in Japan, including SSEs and healthcare resource use. Expert Rev Pharmacoecon Outcomes Res. 2017;17(5):511–517.

PMID 28277852 DOIObservational

García Trevijano Cabetas M, et al. Real-world outcomes of abiraterone and enzalutamide in first-line mCRPC. Eur J Hosp Pharm. 2022;30(5):268–272.

PMID 34620687 DOIObservational

Body JJ, et al. Real-world study assessing use of bone-targeted agents and impact on bone metastases in prostate cancer in Europe. J Bone Oncol. 2019;14:100212.

PMID 30627511 DOIObservational

Patel CM, Wadas TJ, Shiozawa Y. Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Bone Metastases. Molecules. 2021;26(8).

PMID 33918705 DOIReview

Blacksburg SR, Witten MR, Haas JA. Integrating bone targeting radiopharmaceuticals into the management of patients with mCRPC with symptomatic bone metastases. Curr Treat Options Oncol. 2015;16(3):325.

PMID 25777571 DOIReview

Zustovich F, Fabiani F. Therapeutic opportunities for CRPC patients with bone metastases. Crit Rev Oncol Hematol. 2014;91(2):197–209.

PMID 24503416 DOIReview

Sindhu KK, Nehlsen AD, Stock RG. Radium-223 for Metastatic Castrate-Resistant Prostate Cancer. Pract Radiat Oncol. 2022;12(4):312–316.

PMID 35717046 DOIReview

Shirley M, McCormack PL. Radium-223 dichloride: a review of its use in patients with mCRPC with symptomatic bone metastases. Drugs. 2014;74(5):579–586.

PMID 24610703 DOIReview

Picciotto M, et al. Emerging role of Radium-223 in the growing therapeutic armamentarium of mCRPC. Expert Opin Pharmacother. 2017;18(9):899–908.

PMID 28449621 DOIReview

Body JJ, Casimiro S, Costa L. Targeting bone metastases in prostate cancer: improving clinical outcome. Nat Rev Urol. 2015;12(6):340–356.

PMID 26119830 DOIReview

Winter BM, von Rundstedt FC, Grimm MO. Radium-223 dichloride in CRPC. Urologe A. 2017;56(11):1435–1439.

PMID 29022046 DOIReview

Gareen IF, et al. Hospice Admission and Survival After F-Fluoride PET for Evaluation of Osseous Metastatic Disease in the NOPR. J Nucl Med. 2018;59(3):427–433.

PMID 29284672 DOIObservational

Collins A, et al. Transition Points for the Routine Integration of Palliative Care in Patients With Advanced Cancer. J Pain Symptom Manage. 2018;56(2):185–194.

PMID 29608934 DOIObservational

Ellsworth SG, et al. Patterns of care among patients receiving RT for bone metastases at a large academic institution. Int J Radiat Oncol. 2014;89(5):1100–1105.

PMID 25035214 DOIObservational

Fischer-Valuck BW, et al. Palliative RT for prostate cancer with bone metastases at diagnosis: patterns of care and OS. Cancer Med. 2018;7(9):4240–4250.

PMID 30120817 DOIObservational

Spencer BA, et al. Metastatic epidural spinal cord compression among elderly patients with advanced prostate cancer. Support Care Cancer. 2014;22(6):1549–1555.

PMID 24429841 DOIObservational

Chohan MO, et al. Surgical Decompression of High-Grade Spinal Cord Compression from Hormone-Refractory Metastatic Prostate Cancer. Neurosurgery. 2018;82(5):670–677.

PMID 28541420 DOIObservational

Rades D, et al. Metastatic Spinal Cord Compression: A Survival Score Particularly Developed for Elderly Prostate Cancer Patients. Anticancer Res. 2015;35(11):6189–6192.

PMID 26504049Observational

Loblaw DA, et al. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: Cancer Care Ontario NODSG. J Clin Oncol. 2005;23(9):2028–2037.

PMID 15774794 DOISystematic Review

Ribas ES, Schiff D. Spinal cord compression. Curr Treat Options Neurol. 2012;14(4):391–401.

PMID 22547256 DOIReview

Vayne-Bossert P, et al. Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery). Cochrane Database Syst Rev. 2017;7:CD012002.

PMID 28671265 DOISystematic Review

Nguyen PL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825–836.

PMID 25097095 DOIReview

Ahmadi H, Daneshmand S. Androgen deprivation therapy: evidence-based management of side effects. BJU Int. 2013;111(4):543–548.

PMID 23351025 DOIReview

Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2013;189(1 Suppl):S34–S42.

PMID 23234628 DOIReview

Isbarn H, et al. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol. 2009;55(1):62–75.

PMID 18945543 DOIReview

Soeyonggo T, et al. Information needs of men on androgen deprivation therapy. BJU Int. 2012;109(10):1503–1509.

PMID 21883845 DOIObservational

Soeyonggo T, et al. National survey addressing PCP knowledge of ADT side effects in prostate cancer. Can Urol Assoc J. 2014;8(3–4):E227–E234.

PMID 24839488 DOIObservational

Bargiota A, et al. Adverse effects of ADT in patients with prostate cancer: Focus on muscle and bone health. J BUON. 2020;25(3):1286–1294.

PMID 32862568Review

Newton RU, Galvão DA. Exercise in prevention and management of cancer (including ADT-related adverse effects in prostate cancer). Curr Treat Options Oncol. 2008;9(2–3):135–146.

PMID 18704691 DOIReview

Trost LW, et al. ADT impact on quality of life and cardiovascular health, monitoring therapeutic replacement. J Sex Med. 2013;10 Suppl 1:84–101.

PMID 23387914 DOIReview

Takayama KI. Biological and clinical advances of androgen receptor function in age-related diseases and cancer. Endocr J. 2017;64(10):933–946.

PMID 28824023 DOIReview

Gay HA, et al. EBRT or brachytherapy with or without NADT: results of a multicenter prospective study of QoL. Int J Radiat Oncol Biol Phys. 2017;98(2):304–317.

PMID 28463150 DOIObservational

Tang M, et al. Efficacy and outcome of holmium laser enucleation of prostate in patients with urinary retention due to advanced prostate cancer. Lasers Med Sci. 2020;35(6):1307–1313.

PMID 31768690 DOIObservational

Moyad MA. Nutraceuticals and Phytotherapy in Men's Health: Antioxidants, Pro-oxidants, and Lifestyle Changes. Urol Clin North Am. 2022;49(2):239–248.

PMID 35428430 DOIReview

Grammatikopoulou MG, et al. Dietary Factors and Supplements Influencing PSA in Men with Prostate Cancer: Evidence Analysis Based on RCTs. Nutrients. 2020;12(10).

PMID 33003518 DOISystematic Review

Sharifi-Zahabi E, et al. The effect of lycopene supplement from different sources on PSA: a systematic review and meta-analysis of RCTs. Complement Ther Med. 2022;64:102801.

PMID 35031434 DOIMeta-Analysis

Bunker CH, et al. A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk. Nutr Cancer. 2007;57(2):130–137.

PMID 17571945 DOIRCT

Wyatt GK, et al. Saw Palmetto for Symptom Management During Radiation Therapy for Prostate Cancer. J Pain Symptom Manage. 2016;51(6):1046–1054.

PMID 26891611 DOIRCT

Ng AC, Cheng KF, Leung PC. Prospective trial of herbal formula BYSH and saw palmetto in patients with hormone-refractory prostate cancer. Recent Pat Inflamm Allergy Drug Discov. 2014;8(3):196–202.

PMID 25163818 DOIRCT

Vemana G, Hamilton RJ, Andriole GL, Freedland SJ. Chemoprevention of prostate cancer (including SELECT trial findings). Annu Rev Med. 2014;65:111–123.

PMID 24188663 DOIReview

Lane JA, et al. ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer. Cancer Prev Res (Phila). 2018;11(11):687–696.

PMID 30309839 DOIRCT

Van Patten CL, et al. Diet and dietary supplement intervention trials for the prevention of prostate cancer recurrence: a review of RCT evidence. J Urol. 2009;180(6):2314–2321.

PMID 18930254 DOISystematic Review

Atenguena EO, et al. Epidemiological, clinical and therapeutic characteristics of metastatic spinal cord compression in prostate cancer patients in Cameroon. Pan Afr Med J. 2022;41:163.

PMID 35655677 DOIObservational

Rot I, Wassersug RJ, Walker LM. What do urologists think patients need to know when starting on androgen deprivation therapy? Transl Androl Urol. 2016;5(2):235–247.

PMID 27141453 DOIObservational

Yeku O, Slovin SF. Metabolism and pharmacokinetics of radium-223 in prostate cancer. Expert Opin Drug Metab Toxicol. 2015;11(5):843–849.

PMID 25740232 DOIExpert

terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. © Terminal2 | terminal2.care

📝

Private Notes

Session notes — not saved to any server. Clears when you close the tab.

Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.